Medindia

X

GenoLogics Releases BioVault Biospecimen Management Software in Partnership With GenVault Corporation

Wednesday, May 28, 2008 General News J E 4
Advertisement
CARLSBAD, Calif., May 27 GenoLogics, the leading developerof translational research informatics solutions for life sciencesorganizations, today announced its partnership with GenVault Corporation forits biospecimen data management system, BioVault.

"We recognize the significance of biospecimen repositories with wellannotated clinical information to biomedical research and have embarked on astrategic endeavor to provide a full product line of integrated softwaresystems", says GenoLogics' VP of Market Strategy, James DeGreef. "We areexcited about releasing our first biomedical product, BioVault, which is partof our total solution to help clients better manage their biosamples andrelated data".

GenoLogics launched its Biomedical Informatics software solution to trackobservational studies, collect patient data at remote sites, providebiospecimen and clinical annotations management and facilitate researchersquerying on clinical information and requesting samples. The suite iscomprised of five integrated products, including BioVault for biospecimenmanagement, which GenoLogics is partnering with GenVault, a leading vendor ofbiosample management solutions.

"Our experience with helping clients to stabilize their biosamples at roomtemperature and seamlessly manage their transport, storage and retrievalcomplements GenoLogics' experience in providing lab and data managementsoftware solutions to research organizations", says Dr. David Wellis, CEO ofGenVault. "Our biospecimen consumable, hardware and software technologies werebuilt to allow for full integration with software applications such as theBiomedical Informatics products GenoLogics is building".

To provide clients with highly integrated world-class solutions,GenoLogics works with several leading technology vendors as part of itspartner ecosystem. "We see the GenVault technology as very synergistic withour software solutions and believe that together we are providing our clientswith a technically better solution to manage their biosamples and integratewith their data management systems", says James DeGreef.

GenoLogics is developing their Biomedical Informatics product line as acomplement to their existing Research Informatics product line. The biomedicaland research product lines, combined with the ability to provide datawarehouse services, enables GenoLogics to deploy an effective solution forclients to manage their translational research initiatives.

"Our new Biomedical Informatics product line is a strategic addition toour company's offerings, allowing us to provide a more comprehensive datamanagement solution to our life sciences clients", says Michael Ball, CEO forGenoLogics. "The new breadth of informatics solutions provided by GenoLogicswill enable our customers to pursue their translational research vision moreefficiently and effectively by seamlessly connecting their biomedical andresearch data into one platform".

About GenoLogics

GenoLogics provides enterprise level lab and scientific data managementsolutions to the discovery life sciences market. Our science purposed modulesare complemented by a highly configurable, integrating lab informaticsplatform and a broad range of professional services. The GenoLogics LIMSplatform is scalable to service many different labs and sciences across anorganization including genomics, proteomics and other discovery researchareas. As well, our platform can provide significant value to organizationswith a systems biology or translational medicine initiative. For moreinformation, please visit http://www.genologics.com.

About GenVault

GenVault is the global leader in providing biosample workflow, transportand storage solutions for genomic medicine, discovery and identification.Today, GenVault is empowering over 150 pharmaceutical companies, medicalcenters, academic institutions and law enforcemen
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
WorldHeart Announces Delisting Appeal Received and...
S
WuXi PharmaTech Announces First Quarter 2008 Resul...